Segundas líneas en cáncer de ovario ¿hay un estándar?

Abstract

Recurrent ovarian carcinoma is usually incurable and palliative chemotherapy is the treatment of choice. In those patients considered as platinum-sensitive (with a platinum-free interval over 6 months) we have enough evidence to recommend carboplatin-based combination chemotherapy, due to the impact in survival observed in clinical trials comparing carboplatin monotherapy versus combination chemotherapy. On the other band, in those patient with progression to a platinum based chemotherapy (refractory) or with relapse in a period of less than 6 months (resistant), sequential monotherapy with active drugs in the second line is the recommended approach. The absence of a standard drug in this context makes that the choice should be based on toxicity criteria, quality of life and the preference of the patient.